Table 1.

In vitro characterization of novel anti-uPAR antibodies. Tras: Trastuzumab. hIgG1: Human isotype control. Dash (-): Not determined. NA: Not applicable.

Anti-uPAR antibody	Cellular recognition		Human uPAR binding	Cyno uPAR binding	ADCC NK-92		ADCC PBMCs		ADC Cytotoxicity		Adhesion blocking
ID number	Max MFI	EC50 (95% CI, nM)	EC50 (95% CI, nM)	EC50 (95% CI, nM)	Max%	EC50 (nM)	Max%	EC50 (nM)	Max%	EC50 (nM)	IC50 (95% CI, µM)
1474	1740	0.51 (0.22–1.07)	0.14 (0.11–0.21)	0.20 (0.15–0.29)	15.56	0.73	NA	NA	NA	NA	NA
3159	1830	0.92 (0.20–5.60)	0.53 (0.38–0.87)	0.27 (0.20–0.42)	28.18	0.89	47.41	0.11	32.02	0.75	1.61 (0.71–3.45)
3639	2053	1.42 (0.50–5.32)	0.52 (0.39–0.80)	0.19 (0.17–0.21)	34.09	5.95	57.06	0.53	2.32	-	>10
5016	2429	0.51 (0.16–1.27)	0.75 (0.58–1.08)	0.11 (0.10–0.15)	23.73	3.12	49.56	0.12	0	-	>10
6312	1809	4.53 (2.07–11.22)	0.28 (0.22–0.40)	0.21 (0.18–0.27)	16.44	4.03	NA	NA	NA	NA	NA
6553	2353	3.76 (1.74–9.17)	0.33 (0.26–0.46)	0.21 (0.16–0.29)	17.44	5.6	NA	NA	NA	NA	NA
8163	2330	0.69 (<53.38)	0.41 (0.28–0.79)	0.15 (0.13–0.19)	18.81	1.14	57.55	0.09	28.7	0.57	5.40 (2.11–31.5)
9538	1270	0.46 (0.25–0.80)	0.67 (0.59–0.78)	1.12 (0.96–1.37)	29.71	50.2	45.64	13.01	4.26	-	3.51 (1.80–8.40)
11513	1642	0.39 (0.29–0.51)	0.75 (0.58–1.08)	0.28 (0.22–0.39)	21.60	-	NA	NA	NA	NA	NA
11857	1936	2.07 (0.52–16.00)	0.52 (0.39–0.80)	0.18 (0.16–0.22)	27.16	5.59	52.04	0.35	35.16	0.76	0.94 (0.17–76.9)
13706	1669	7.61 (4.09–14.66)	0.53 (0.38–0.87)	0.30 (0.26–0.39)	54.56	4.85	65.66	0.79	3.24	-	>10
2G10	2204	16.65 (12.87–21.56)	0.26 (0.19–0.46)	-	33.92	22.53	65.45	8.65	4.9	-	3.46 (0.96–33.0)
3C6	971	-	0.28 (0.22–0.40)	-	NA	NA	NA	NA	1.42	-	0.81 (0.43–1.50)
hIgG1	155.3	-	NA	NA	0.47	-	4.8	-	NA	NA	NA
Tras	841.8	3.65 (0.67–70.55)	NA	NA	NA	NA	NA	NA	NA	NA	NA